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Dilated cardiomyopathy (DCM) is a myocardial disease characterized by progressive depression of
myocardial contractile function and ventricular dilatation. Thirty percent of DCM patients belong
to the inherited genetic form; the rest may be idiopathic, viral, autoimmune, or immune-mediated
associated with a viral infection. Disturbances in humoral and cellular immunity have been
described in cases of myocarditis and DCM. A number of autoantibodies against cardiac cell pro-
teins have been identified in DCM. In this study, we have profiled the autoantibody repertoire of
plasma from DCM patients against a human protein array consisting of 37 200 redundant,
recombinant human proteins and performed qualitative and quantitative validation of these puta-
tive autoantigens on protein microarrays to identify novel putative DCM specific autoantigens. In
addition to analyzing the whole IgG autoantibody repertoire, we have also analyzed the IgG3
antibody repertoire in the plasma samples to study the characteristics of IgG3 subclass antibodies.
By combining screening of a protein expression library with protein microarray technology, we
have detected 26proteins identified by the IgG antibody repertoire and 6 proteins bound by the
IgG3 subclass. Several of these autoantibodies found in plasma of DCM patients, such as the
autoantibody against the Kv channel-interacting protein, are associated with heart failure.
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1 Introduction
Dilated cardiomyopathy (DCM) is a heart muscle disease
characterized by progressive depression of myocardial con-
tractile function and by ventricular dilatation [1]. DCM is a
relevant cause of heart failure and a common indication for
heart transplantation. A subgroup of DCM patients belong to
the inherited genetic form, the rest may be idiopathic, viral,
autoimmune, or immune-mediated associated with a viral
infection [1, 2]. Despite recent improvements in therapy,
both incidence and mortality of DCM are still high [3].
Recently, evidence has emerged that inflammatory and
autoimmune mechanisms play an important role in the
pathogenesis of DCM [4, 5]. At least, one-third of DCM
patients reveal IgG cardiac-specific antibodies [6]. It has been
shown that the injection of blood lymphocytes from DCM
patients containing human autoantibodies induces early
stage of heart failure in mice [7]. Furthermore, the extraction
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of circulating autoantibodies by immunoadsorption from
blood of patients with DCM leads to an improvement in car-
diac function indicating an active role of these auto-
antibodies in the pathogenesis of DCM [8–12]. Apart from
simply reflecting an inflammatory response to myocyte
necrosis, which would indicate an epiphenomenon or dis-
ease markers, such antibodies could initiate the disease pro-
cess or contribute to the progression of myocardial con-
tractile malfunction.
In particular, autoantibodies against cellular cardiac
proteins, like G-protein coupled receptors (e.g., b1-adrener-
gic receptors [13, 14]) and muscarinergic receptors (M2),
have been identified [15]. In addition, antibodies against
membrane components and mitochondrial proteins, espe-
cially against the ADP/ATP-carrier protein of the inner
mitochondrial membrane, have been associated with the
disease [16, 17]. It has been shown that autoantibodies
against the ADP/ATP-carrier protein cause a reduction in
cardiac function by enhancing the calcium channel cur-
rent, which leads to calcium overload [18, 19]. Also, auto-
antibodies against myosin light-chain-1, tropomyosin,
HSP-60, and a- and b-myosin heavy-chain isoforms have
been observed [20, 21]. Analysis of IgG subclasses against
a- and b-myosin heavy-chain protein indicated increased
levels of IgG3 in DCM patients [22]. Recent data indicate
that immunoadsorption removes functionally active nega-
tive ionotropic antibodies from the plasma of patients with
DCM [23]. These antibodies belong to the IgG subclass 3
[12].
Experimental studies yielded evidence of direct involve-
ment of autoimmunity in the pathogenesis of DCM. Mice
deficient in the programmed cell death-1 (PD-1) immu-
noinhibitory coreceptor develop DCM. Sera of these mice
contained high-titer autoantibodies against a heart-specific
30-kDa protein [24]. Recently, this protein was identified as
cardiac troponin I [25]. Finally, using an experimental animal
model with rats sensitized against the b1-receptor, direct evi-
dence was demonstrated for b1-receptor antibodies as a cause
of DCM [13].
Autoimmune diseases are characterized by the presence
of low- and high-affinity autoantibodies [26]. Although the
pathogenic role for most of the autoantibodies in various
autoimmune diseases is not clear, the specificity and patho-
genicity of the autoimmune response may present an
important tool for diagnosis, classification, and prognosis
[27, 28]. Additionally, profiling the autoantibody repertoire
may give elucidation into the pathophysiology of auto-
immunity, enabling novel treatments such as antigen-toler-
ising therapy [29, 30]. Protein microarrays have been used for
detection and validation of autoantibodies in serum or
plasma [31–33].
In this study, we combine protein array technology
with the use of large cDNA expression libraries. Büssow et
al. [34] have previously shown that cDNA libraries, cloned
into an Escherichia coli expression vector, can be screened
for protein expression on high-density filter membranes.
Using robot technology [35], a human fetal brain cDNA
expression library (hEx1) was picked into microtiter plates
and high-density protein arrays were generated on filter
membranes followed by in situ protein expression. This
approach was extended to automated spotting of protein
microarrays from crude lysates of the expression cultures
[33]. In an initial analysis of this library, more than 66% of
the clones contain inserts in the correct reading frame.
Sixty-four percent of these clones comprise full-length pro-
teins [33]. Furthermore, these expressed proteins are suit-
able for either MALDI-TOF-MS or functional screening
assays [36, 37].
By combining the expression library approach with pro-
tein array technology, we have profiled the antibody reper-
toire in plasma of DCM patients on a human protein array
consisting of 37 200 redundant, recombinant human pro-
teins, followed by qualitative and quantitative validation of
putative autoantigens on protein microarrays.
2 Materials and methods
2.1 Patient data
Included in this study were patients suffering from DCM
(mean age 52.8 6 8 years, NYHA III-IV) and left ventricular
dysfunction (left ventricular ejection fraction (LVEF) , 35%;
mean LVEF = 26 6 7%; left ventricular internal diameter in
diastole = 776 13mm). Coronary heart disease was excluded
by coronary angiography. Patients were excluded if they had a
history of arterial hypertension, myocardial infarction, heart
failure due to other known origins (e.g., primary valvular
disease), or if they had suffered from active infectious dis-
eases, cancer, or chronic alcoholism. From all patients
plasma samples were used for screening of cardiac auto-
antibodies: For control purposes, we used plasma from gen-
der- and age-matched patients (controls). In these patients,
coronary heart disease was excluded by coronary angiog-
raphy which was performed for clinical reasons. Normal left
ventricular function was documented by left ventricular
angiography.
2.2 Expression vector and bacterial strain
An expression subset consisting of 37 200 clones of a cDNA
library (hEx1) from human fetal brain cloned in the expres-
sion vector pQE30NST (GenBank Accession No. AF074376)
and transformed into E. coli strain SCS1 (Stratagene) [34]
was used for autoantibody profiling.
2.3 Sequence analysis of expression clones
cDNA inserts were PCR amplified and tag-sequenced as
previously described [36]. The sequences were searched
against public databases (NCBI) [38].
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2.4 Plasma screening on high-density protein arrays
High-density protein arrays of the protein expression set of the
hEx1 library were obtained from the German Resource Center
for Genome Research (RZPD) and prepared as described [34].
For plasma screening, the filters were blocked in 3% nonfat, dry
milk powder inTBST (TBS, 0.1% v/vTween 20) for 2 h,washed
twice in TBSTand subsequently incubated with plasma diluted
1:20 in 2% w/v BSA/TBST for 16 h. After three 30 min TBST
washes and subsequent incubationwith the secondary antibody
(either mouse-antihuman-IgG, Sigma, or 1:5000 dilution,
mouse-antihuman-IgG3, Sigma, 1:400 dilution as appropriate)
in 2% w/v BSA/TBST, the filters were washed three times for
30 min in TBST. This was followed by incubation with the ter-
tiary antibody (rabbit-antimouse-IgG-AP, Sigma, 1:5000 dilu-
tion) in 2% w/v BSA/TBST. Subsequently, the filters were
washed three times in TBST-T for 20 min, then for 10 min in
TBS, and then washed for 10 min in AP buffer (1 mM MgCl2,
0.1 M Tris pH 9.5), followed by incubation in 25 mM Attophos
(JBL Scientific) in AP buffer for 5 min. The filters were illumi-
natedwith long-waveUV light and the imageswere taken using
a high-resolution CCD detection system (Fuji). Image analysis
was done using VisualGrid.
2.5 Protein expression and purification in high
throughput
Each protein was expressed twice in 1 mL cultures in deep-
well microtiter plates. The protein extracts of each culture
were generated as described [39] and combined. Proteins
were purified as previously described [36].
2.6 Generation of protein microarrays
TheFASTslides (Schleicher&Schuell)were placed in aQ-Array
System (Genetix, New Milton, UK), equipped with humidity
control (65%) and 16 or 24 blunt-ended stainless steel print tips
with a tip diameter of 150 mm.All protein antigenswere spotted
in three different concentrations (undiluted, 1:2, and 1:5 dilut-
ed). For most of the proteins, spotting of the undiluted purified
proteins leads to immobilization of 15 fmol protein per spot on
the microarray (undiluted: 15 fmol; 1:2: 8 fmol; 1:5: 3 fmol,
respectively). Each protein microarray includes several control
spots, e.g., human or mouse IgG antibody in three concentra-
tions (human IgG: 1:1000, 1:2500, and 1:5000; mouse-antihu-
man-IgG: 1:1000, 1:2500, and 1:5000; mouse-antihuman-IgG3:
1:500, 1:1000, and 1:2500) as well as a control protein, human
myosin (undiluted, 1:2, and 1:5 diluted) which is a common
naturally occurring autoantigen.
For the so-called IgG protein chip a 666 spot pattern was
printed onto the slides, including all proteins, antibodies and
controls and their dilution as duplicates. For the so-called
IgG3 protein chip a 565 spot pattern was printed onto the
slides, where each protein and its dilutions were present four
times. In all cases, each spot was loaded once transferring
2 nL per spot.
2.7 Plasma screening on protein microarrays
After spotting, the protein chips were blocked in 2% w/v
BSA (BSA/TBST, 0.1% v/v Tween 20) at room temperature
and the plasmas were added diluted either 1:100 (IgG) or
1:50 (IgG3), as appropriate, in 2% w/v BSA/TBST. The pro-
tein chips were incubated in a humidified atmosphere for
16 h at 47C. Following three 30-min TBST washes and sub-
sequent incubation with the secondary antibody (mouse-
antihuman-IgG, Sigma, 1:5000 dilution, mouse-antihuman-
IgG3, Sigma, 1:400) in 2% w/v BSA/TBST, the protein chips
were washed three times for 20 min in TBST. This was fol-
lowed by incubation with the tertiary antibody (rabbit-anti-
mouse-IgG-Cy3 or rabbit-antimouse-IgG-Cy5, Dianova,
1:800 dilution) in 2% w/v BSA/TBST. Subsequently, the
chips were washed three times, each in TBST for 20 min. All
secondary and tertiary antibody incubation steps were per-
formed for 1 h at room temperature and carried out in a 200-
mL volume underneath a cover slide in the dark. These pro-
tein chips were imaged using a confocal microarray reader
(ScanArray 4000, Perkin Elmer Life Science).
2.8 Bioinformatic analysis
Image analysis was performed using GenePix Pro 3.0 (Axon)
or ScanArray Express (Perkin Elmer Life Science), and the
mean intensity (median background subtracted) was deter-
mined for each protein feature. The average value of the
protein duplicates or quadruplicates was calculated (aver-
ageprotein of patient plasman or control plasman value) fol-
lowed by the determination of the quality of the screen by
calculating the CV of the control proteins human IgG and
mouse IgG, respectively. These values were also used for
interchip normalization. Each chip was normalized against
the RGSHis6 epitope tag intensity, which reflects the appro-
priate protein concentration. The mean of all average inten-
sities for each protein spotted and its associated dilutions of
each control plasma (named: averageprotein of control plasman
value) was calculated. In the following, this is called the
“averageprotein6control” value. Dividing the average value of
each individual patient plasma (named: aver-
ageprotein6patient plasman value) by the “averageprotein6con-
trol value” results in the so-called factor F, and for this anal-
ysis we suggested F values above 2 were significant for the
disease.
3 Results and discussion
3.1 Profiling the antibody repertoire against a human
protein array containing 37 200 redundant
proteins
Screening protein arrays with body fluids, such as serum or
plasma from large numbers of patients with an autoimmune
disease, for example rheumatoid arthritis, diabetes, multiple
© 2006 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com
608 S. Horn et al. Proteomics 2006, 6, 605–613
sclerosis, or alopecia would not only allow the identification
of potentially novel autoantigens, but also potentially assist
the prognosis, diagnosis, and subtyping of autoimmune dis-
eases based on the presence of specific autoantibodies [40].
In this study, we used a human high-density protein array
containing 37 200 redundant, recombinant proteins derived
from a human fetal brain expression library. The use of such
a cDNA expression library eliminates the need to construct
individual expression clones for every protein of interest. By
introducing a sequence coding for an affinity tag (e.g., Histi-
dine tag, GST tag) to the 5’ end of the cDNA insert, resulting
expression clones can be rapidly identified by the presence of
the His- or GST-tagged fusion protein. E. coli is most com-
monly used in automated recombinant expression and puri-
fication as it is a robust and convenient host organism [36,
41, 42]. It has to be considered that many eukaryotic proteins
end up in cytoplasmic inclusion bodies when they are
expressed in E. coli and can only be recovered in the dena-
tured state. However, it has been recently demonstrated by
Robinson et al. [32] and Quintana et al. [28] that serum
screening against peptides leads to reasonable results,
showing that antibodies in serum can recognize linear epi-
topes. Therefore, the human high-density protein array con-
taining 37 200 human proteins is an important high-content
protein resource.
These high-density protein arrays were incubated with
plasma from ten patients with DCM. The antibody repertoire
in plasma was detected using antihuman-IgG antibody
(Fig. 1A). Taking into account the characteristics of IgG3
antibodies in DCM patients [11, 22], the IgG3 antibody
repertoire in plasma was also analyzed using antihuman-
IgG3 secondary antibody.
A high reproducibility of over 80% was determined when
separate, independent incubations using the same patient
plasma were performed against two separate human protein
arrays (Fig. 1B). The data sets obtained from ten DCM
patient plasma screenings were compared to ten age- and
sex-matched control plasmas from persons without heart
Figure 1. Plasma screening on high-density protein arrays. (A) A
high-density protein array of the human fetal brain library was
incubated with plasma of a DCM patient. IgG3-specific antibodies
were detected using an antihuman-IgG3 secondary antibody.
Positive clones were identified using the 565pattern (left panel).
(B) Reproducibility of two different high-density protein arrays
incubated with the same patient plasma. A reproducibility of over
80% was determined.
diseases, and to background incubations with antihuman-
IgG and antihuman-IgG3. We postulate that autoimmune
diseases are correlated with a specific autoimmune response
leading to a specific autoantibody profile. When comparing
the control and DCM results, we found that all proteins that
were recognized by antibodies in two or more control plas-
mas were also seen in DCM patient plasma, i.e., in this study
we did not find a healthy, control-associated profile. In con-
trast, we identified a large number of protein antigens in
plasma from both DCM patients and controls, the natural
autoantibody (NAA) profile. IgG antibodies against cytoskel-
etal proteins such as tubulin, its interacting protein stath-
min, and myosin were found in 80% of all samples (disease
and controls). The presence of such natural autoantibodies is
well recognized and they have been found in all individuals
[43, 44]. We determined such NAAs to ascertain the quality of
the used plasma. Here, we used skeletal myosin as a marker
to monitor the plasma quality and identified 88% of the
plasma samples in this study. This confirms other recent
findings [45].
From these data, proteins exclusively detected by anti-
bodies in DCM patient plasma were determined. When we
considered proteins, which were detected by antibodies in
two or more of the ten DCM patients, but were not recog-
nized by plasma from the ten controls, we identified two
subsets deriving from the IgG (48 proteins) and IgG3
(32 proteins) antibody profiling experiments. 5’-tag sequenc-
ing of these clones was performed and their sequences were
used for BLAST searches against the public databases
including GenBank and UniGene [38].
Since the proteins on the high-density protein arrays
have not been immobilized in a purified state, this may
result in unspecific cross-reactions or higher S/Ns. Conse-
quently, we further characterized these putative DCM spe-
cific protein subsets by using highly sensitive protein micro-
arrays comprising purified proteins. In addition to their
much higher sensitivity, protein microarrays require very
small amounts of samples and enable a higher throughput
due to their small size, when compared with the larger high-
density protein arrays. Therefore, we used the protein
microarrays for qualitative and quantitative validation of the
putative autoantigens using a larger patient and control
plasma collection.
3.2 Qualitative and quantitative validation of
putative autoantigens on protein microarrays
The recombinant proteins selected above were expressed
from the bacterial clones and purified, in parallel, under
denaturing conditions. This corresponds to the state of the
proteins immobilized on the PVDF protein array. Following
high-throughput protein expression and purification, three
concentrations of these recombinant purified proteins were
generated, namely undiluted, 1:2, and 1:5 dilution. For most
of the proteins, spotting of the undiluted protein leads to
immobilization of 15 fmol of protein per spot on the micro-
© 2006 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com
Proteomics 2006, 6, 605–613 Protein Arrays 609
array (undiluted, ,15 fmol, 1:2 ,8 fmol, 1:5: ,3 fmol,
respectively). Each protein sample was spotted in duplicate,
onto three fields of a microscope glass slide coated with a 3-D
NC-based matrix, using a transfer stamp consisting of
16 pins with a 150 mm tip size. Each set of proteins derived
from the IgG and IgG3 antibody profiling experiments were
immobilized onto a single chip leading to a so-called DCM-
IgG or DCM-IgG3 protein microarray. To enable inter- and
intrachip image analysis, as well as process controlling, hu-
man IgG (in the form of human plasma) and mouse IgG (in
the form of mouse-antihuman-IgG/IgG3) were included in
different dilutions (human IgG: 1:1000, 1:2500, and 1:5000
dilutions; mouse IgG: 1:1000, 1:2500, and 1:5000 dilutions;
IgG3: 1:500, 1:1000, and 1:2500 dilutions). Skeletal myosin
protein was also included as a positive control in the IgG chip
as most of the plasma samples contain IgG antibodies
against this protein. It has been shown that 90–95% of indi-
viduals have natural autoantibodies against skeletal myosin
[45]. The DCM-IgG and DCM-IgG3 protein microarrays were
incubated with 56 DCM patient plasmas, which include the
original ten DCM patient plasmas used in the initial protein
PVDF array screening. In addition, 30 corresponding age-
and sex-matching healthy control plasmas were also
screened, these included the original ten control plasmas
used in the first screening of the protein PVDF arrays
(Fig. 2). Additionally, a protein microarray from each spotted
chip batch was incubated with an antiRGSHis6 antibody di-
rected against the amino-terminal RGSHis6 tag of the
immobilized recombinant protein. The resulting intensities,
which reflect the corresponding protein concentration, were
used for normalization (by dividing each intensity value
from the plasma incubation by the corresponding RGSHis6
intensity value). To analyze the quality of the plasmas, the
average intensity of the control protein, myosin, was deter-
mined for the patient and control plasma groups. A low
Figure 2. DCM-IgG microarray consisting of 48putative DCM
associated proteins and several control proteins spotted onto
three identical fields on a coated glass slide. (A) DCM-IgG micro-
array incubated with an antibody directed against the RGSHis6
epitope. (B) Incubation of the DCM-IgG microarray with a patient
plasma sample (middle field) and an enlarged extension of dif-
ferentially detected proteins when compared to a sex- and age-
matched control plasma sample (C).
SD was observed, resulting in a CV of 5–25%. This indicates
a comparable quality of the patient and control plasma. The
intensities of six plasmas of the patient group (13%) and
three plasmas of the control group (10%) were below back-
ground. Therefore, more than 88% of the plasmas show
natural autoantibodies against this type of myosin confirm-
ing previously presented data [45].
To analyze the quality of the plasma screening, the CVs of
the process control antigens, namely human IgG and
mouse IgG/IgG3, were determined for each incubated
microarray and the average CV was then calculated. The
analysis of the IgG screening shows an average CVof mouse
IgG of 46% and of mouse IgG3 of 35%. For further analysis,
for each group, i.e., the control plasma group and the patient
plasma group, respectively, an average signal intensity of the
control proteins was determined. Here, we observed that
nearly all intensities of the control proteins were lower in the
control plasma group by a factor of 0.7. Consequently, we
applied this factor to the intensity values of all proteins of the
patient plasma group.
The IgG3 screening revealed an average CV for human
IgG3 of 27% and of mouse IgG of 32%. These results reflect
a good quality for the IgG3 screening.
Following bioinformatic analysis of these results, signifi-
cant differences between patient and control plasmas have
been determined for 10 proteins in all dilutions and 16 pro-
teins in the 1:5 dilution on the DCM-IgG. Six proteins which
were predominantly detected by patient plasmas have been
identified on the DCM-IgG3 protein microarray (Table 1).
Some of the putative DCM associated protein autoantigens
showed higher F values when the diluted plasma was used.
The pathophysiological role of the proteins identified
here will need to be determined in future studies.
3.3 Remarks on putative autoantigens
Natural autoantibodies against cytoskeletal proteins such as
tubulin, its interacting protein stathmin, and myosin were
found in over 80% of diseased and control samples.
We have not identified any known DCM markers such as
the b-receptor [13]. Based on sequence analysis of approxi-
mately 8000 clones of the nonredundant Uniclone set [46,
47], the conclusion is justified that the library does not con-
tain such known DCM markers. Basically, we detected pro-
teins with no clear pathophysiological role, so that the
importance of each of the proteins identified has to be
detected in further studies.
Previous research has investigated the function of some
of the proteins identified by our protein array technology.
Speculation is provided that these proteins also play a role in
cardiac function and hence may be involved in cardiovas-
cular diseases. However, it is important to point out that a
potential role in DCM must be investigated by further stud-
ies. Below, we discuss the role of some of the identified pro-
teins (a–h).
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Table 1. Protein antigens detected by plasma from DCM patients and their cellular location or function




Accession no. Positive patients (in % for
plasma dilutions)
Undiluted 1:2 1:5
Low density lipoprotein-related protein associated protein 1
(LRPAP1)
IgG NM_002337 46 59 61
Plasma/sarcolemmal/peroxisomal membrane associated
Choline kinase-like (CHKL), transcript variant 2 IgG3 NG_003100 14 50 16
Kv channel–interacting protein 1 (KCNIP1) IgG NM_014592 23 50 50
Peroxisome biogenesis factor 13 (PEX13) IgG NM_002618 48 52 63
PAP-2-like protein 2 (PHP2) IgG AF357888 78
Nuclear
Neural proliferation, differentiation, and control, 1 (NPDC1) IgG NM_015392 52 54 61
PCF11p homolog (PCF11) IgG CD579726 48 63 63
CDC37 cell division cycle 37 homolog (Saccharomyces cerevisiae)
(CDC37)
IgG NM_007065 30 54 52
Similar to CGI-30 protein, clone IMAGE:5189198 IgG AU099517 67
RNA binding motif protein 6 (RBM6) IgG NM_005777 57
Neurogenic differentiation 2 (NEUROD2) IgG NM_006160 54
Nuclease sensitive element binding protein 1 (NSEP1) IgG XM_059214 61
Zinc finger protein 142 (ZNF142) IgG NM_005081 63
BAC clone RP11-367J11 from 4 IgG AC097382 52
Similar to Rec8p, a meiotic recombinant and sister chromatid
cohesion phosphoprotein of the rad21p family
IgG BC010887 50
Immunosystem-mediated
HLA class II associated protein I IgG 82
Rapamycin binding protein (FK506) IgG M96256 54
Cytoplasma
Tubulin, alpha 3 IgG3 BC050637 56 20 22
Mitochondria/endoplasmatic reticulum
NDRG family member 4 (NDRG4) IgG3 NM_022910 52 34 10
Proteasome
Ubiquitin-specific protease 47 (USP47) IgG BC047044 44 50 63
NAC alpha mRNA IgG AY034001 41 50 63
Heat shock 70 kDa protein 4 (HSPA4) IgG XM_114482 70
Unknown
Chromosome 7 clone RP11-309L24 IgG AC025594 55 58 78
Chromosome 7 clone RP11-148L5 IgG AC083868 59 63 70
Clone IMAGE:4540326 IgG3 BC044933 40 50 58
FLJ00116 protein IgG3 AK024506 26 52 40
cDNA DKFZp667L0421 IgG3 AL833672 44 56 24
Hypothetical protein MGC15730 IgG NM_032880 63
BAC clone RP11-367J11 from 4 IgG AC097382 52
Sequence from clone RP11-342C24 on chromosome 10 IgG AL603982 59
Hypothetical protein FLJ20203 IgG NM_017710 57
cDNA DKFZp761F069 (from clone DKFZp761F069) IgG AL136596 52
BAC clone RP11-535F1 from 7 IgG AC073422 67
(a) For example, the gene coding for LRPAP1 has been
shown to contain a silent polymorphism among females
with coronary artery disease [48] and an additional variation
in intron 1 of the LRPAP1 gene could contribute to the risk
of developing myocardial infarction [49].
(b) NPDC1 is primarily expressed in the brain and also
relatively high in heart, but is hardly detectable in thymus,
peripheral blood leukocytes, and colon [50]. It has been
shown that NPDC1 down-regulates cell proliferation and
interacts in vitro with the transcription factor E2F-1 and
some cell cycle proteins, such as D-cyclins and cdk2. It is
interesting that the identified CDC37 protein antigen
(Table 1), which regulates the T-cell proliferation, interacts
also with cyclin D. In mammalian two-hybrid experiments, it
was demonstrated that the interaction between NDPC1 and
E2F-1 reduces the binding of E2F-1 to DNA and its tran-
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scriptional activity, suggesting that NPDC-1 could influence
cell cycle progression and neural differentiation through its
association with E2F-1 [51, 52].
(c) The related PAP2 has been shown to be inhibited by
Mg21 and was localized to the sarcolemmal membrane [53].
PAP2 was considered an important enzyme, as it has been
shown to modulate the sarcolemmal levels of phosphatidic
acid and 1,2 diacylglycerol [54]. The importance of phospha-
tidic acid in heart function is evident from its ability to sti-
mulate sarcolemmal Ca21-related transport systems, and
1,2 diacylglycerol has been shown to activate PKC isozymes
which phosphorylate several myocardial proteins including
ion channels [55]. This may be important in relation to DCM,
where a change in intracellular Ca21 homeostase has also
been observed [56, 57].
(d) Mammalian voltage-gated potassium K1 channels are
assemblies of pore-forming a-subunits and modulating b-
subunits. Kv4 a-subunits in the heart and CNS require
recently identified b-subunits of the neuronal calcium sen-
sing protein family called K1 channel-interacting proteins
(KChIPs). KChIP1 belongs to four Kv channel-interacting
proteins, and KChIP1, 3, and 4 are predominantly expressed
in brain whereas KChIP2 is predominantly in heart [58].
Sequence comparison between the identified brain-specific
protein KChIP1 and the heart-specific KChIP2 shows a ho-
mologous region of about 107 aminoacids with a homology
of 71% in this region, suggesting potentially a common epi-
tope or epitopes were recognized (Fig. 3). It has been shown
that KChIP2 (2/2) knock-out mice were highly susceptible
to cardiac arrhythmias and were characterized by a complete
absence of transient outward potassium current [59].
(e) As can be seen in Table 1, we identified tubulin a
using antihuman-IgG3 secondary antibodies. Tubulin a acts
as a subunit of the microtubuli, which are important for cell
structure, the intracellular transporting system, and cell
division [60]. Tubulin is already known to be an autoantigen
in other autoimmune diseases, such as systemic lupus ery-
thematosus [61]. Antibodies against tubulin have also pre-
viously been identified in the plasma of healthy individuals
[45, 62]. However, in this study we have identified tubulin as
a putative IgG3-specific autoantigen in DCM patients.
(f) NDRG4 was detected with the antihuman-IgG3 anti-
body (Table 1) and is expressed in brain and heart [63].
NDRG4 was shown to be involved in the regulation of mito-
genic signaling in vascular smooth muscle cells [64].
(g) We also identified proteins that may be more involved
in the immune system, such as the rapamycin binding pro-
tein (FK506) and human leukocyte antigen (HLA) class II
associated protein 1. FK506 was described as an immuno-
suppressive drug, mediating an inhibition of the calcium-
activated phosphatase calcineurin [65]. Previously, it has
been reported that activated splenic T lymphocytes deficient
in FK506 binding protein 12 have reduced proliferation in
response to IL15 [66]. HLA class II alleles have been found to
be associated to type 1 diabetes mellitus [67].
(h) Other proteins we have identified in this study are
involved in essential components in different biological pro-
cess, but there is no direct connection to heart failure or to
the immune system. For example, PEX13 is a peroxisomal
integral membrane protein and an essential component of
the peroxisomal protein transport machinery. Mutations in
the gene coding for PEX13 lead to peroxisomal metabolic
dysfunction and neurodegenerative disease such as Zellwe-
ger syndrome [68]. However, an involvement in cardiac
function of heart failure has not yet been shown. Also, auto-
antibodies against HSP70 have been found in this study and
HSP70 has been shown to be abundantly expressed in
chronically hypoxic heart tissues, indicating a certain role in
cardioprotection [69–71].
Although several antigens with a closer connection to
heart failure have been identified, the biological role of these
antibodies and their corresponding antigens is not clear. It
remains to be investigated if the antibodies in plasma iden-
tified here cause or have a strong influence on this disease.
For example, it has been shown that the extraction of circu-
lating antibodies (subtype IgG3) from the blood of patients
with DCM by immunoadsorption has led to an improvement
in cardiac function, indicating an active role of these anti-
bodies in the pathogenesis of DCM (Staudt et al. 2002 [12]).
However, it cannot be ruled out that some of these circulat-
ing antibodies in plasma may be a result of cross-reactivity to
other proteins or a secondary product of aberrant pathways
or a result of processes such as apoptosis without direct
influence on the disease.
Hence, we refer to profiling the antibody repertoire in
plasma or serum. The potential of this approach is that it
may identify a disease-associated antibody profile which may
have the potential to improve the diagnosis of disease, where
circulating antibodies play a role, or to potentially improve
the subtyping or perhaps even assist in the analysis of the
progression or prognosis of such disease. The proteins iden-
tified could potentially be candidates for further characteri-
zation and validation as potential diagnostic markers. How-
ever, for such an application, the proteins identified in this
type of analysis would need to be further characterized and
functionally and clinically validated and also required to be
sufficiently disease-associated to make them relevant for di-
agnostic applications. A further application of the type of
study performed here is that the antigens identified may give
insights into the causation of the disease or the mechanism
Figure 3. Amino acid sequence
comparison of KChIP1 and
KChIP2. Sequence identity be-
tween the KChIP1 and KChIP2 on
the amino acid level is over 71%.
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of the progression of such diseases. To improve the power of
this approach, larger numbers of well-characterized diseased
and control patients would need to be included. Moreover,
addition of protein expressing clones derived from a heart
cDNA expression library, or by directed subcloning of spe-
cific proteins, to the present expression library may lead to
improved results.
In general, all of these autoantigens are potential diag-
nostic markers. Their role and their function for the disease
have to be characterized in further projects.
4 Concluding remarks
Our results demonstrate that the novel approach of plasma
screening on an expression library followed by validation on
microarrays is a useful strategy for the identification of
putative autoantigens specific for a particular autoimmune
disease, in this case DCM. Using this approach we were able
to identify 26 autoantigens bound by IgGs and 6 autoanti-
gens specifically bound by the IgG3 subclass. Further steps
are now necessary to functionally characterize the identified
autoantigens, including plasmon resonance binding affinity
studies and in vivo studies in mice.
Such characterized autoantigens are suitable candidates
for different diagnostic and therapeutical applications like an
“autoimmune DCM chip” or the generation of individual
absorption columns for the IA-therapy to remove disease-
associated autoantibodies in a more specific way.
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